# A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01)

> **NCT07700758** · PHASE2 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 15 (estimated)

## Conditions studied

- Malignant Neoplasm

## Interventions

- **DRUG:** Belzutifan

## Key facts

- **NCT ID:** NCT07700758
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-11-23
- **Primary completion:** 2034-01-02
- **Final completion:** 2034-01-02
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07700758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07700758, "A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07700758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*